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Abstract
Neurokinin-1 (NK-1) receptors are present in both the central nervous system and peripheral tissues.
Substance P (SP) is the major ligand and is involved in multiple processes including pain transmission,
vasodilation, modulation of the inflammatory response, as well as the sensory neuronal transmission involved
in stress, anxiety, and emesis. The involvement of NK-1 and SP in the vomiting reflex has led to the
development of NK-1 antagonists to prevent and treat vomiting in human and veterinary medicine.
Maropitant is a potent, selective neurokinin (NK-1) receptor antagonist that blocks the pharmacologic action
of SP in the central nervous system. Maropitant is available in both an injectable and tablet formulation and
approved for use in dogs and cats for the treatment and prevention of vomiting from a variety of clinical causes
and motion sickness. When administered prior to anesthetic premedication, maropitant prevents or
significantly decreases the incidence of opioid-induced vomiting and signs of nausea in dogs and cats.
Maropitant has also been shown to improve postoperative return to feeding and food intake in dogs. The
minimum alveolar concentration of sevoflurage is decreased in both dogs and cats by maropitant, indicating a
potential role as an adjunct analgesic, especially for visceral pain. This article will review the background
information and literature, including clinical recommendations with respect to the perioperative use of
maropitant in canine and feline veterinary patients.
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Abstract: Neurokinin-1 (NK-1) receptors are present in both the central nervous system and 
peripheral tissues. Substance P (SP) is the major ligand and is involved in multiple processes 
including pain transmission, vasodilation, modulation of the inflammatory response, as well as 
the sensory neuronal transmission involved in stress, anxiety, and emesis. The involvement of 
NK-1 and SP in the vomiting reflex has led to the development of NK-1 antagonists to prevent 
and treat vomiting in human and veterinary medicine. Maropitant is a potent, selective neurokinin 
(NK-1) receptor antagonist that blocks the pharmacologic action of SP in the central nervous 
system. Maropitant is available in both an injectable and tablet formulation and approved for 
use in dogs and cats for the treatment and prevention of vomiting from a variety of clinical 
causes and motion sickness. When administered prior to anesthetic premedication, maropitant 
prevents or significantly decreases the incidence of opioid-induced vomiting and signs of nausea 
in dogs and cats. Maropitant has also been shown to improve postoperative return to feeding 
and food intake in dogs. The minimum alveolar concentration of sevoflurage is decreased in 
both dogs and cats by maropitant, indicating a potential role as an adjunct analgesic, especially 
for visceral pain. This article will review the background information and literature, including 
clinical recommendations with respect to the perioperative use of maropitant in canine and 
feline veterinary patients.
Keywords: maropitant, perioperative nausea and vomiting, neurokinin-1 antagonist, Substance P
Introduction
Vomiting and nausea associated with anesthesia is a common occurrence in human 
medicine with an incidence of up to 80% in high-risk patients. The impact on human 
health care costs and patient distress is reflected in the recent publication where a 
systematic review of the literature from the years 2007–2011 identified over 2,600 
articles pertaining to this issue.1 In veterinary medicine, the issue has only recently 
garnered attention. This may reflect an increasing focus on pain management and the 
use of mu-agonist opioid drugs for the treatment of moderate to severe pain. Morphine 
and hydromorphone are commonly used mu-agonist opioids in veterinary patients. 
Hydromorphone is a semi-synthetic derivative of morphine which is more lipid soluble 
and 4–8 times more potent than morphine. Unlike morphine, hydromorphone does not 
increase plasma histamine concentrations after intravenous (IV) administration. The 
incidence of vomiting in dogs has been documented as 50%–75% for morphine and 
44%–100% for hydromorphone.2,3 The incidence of vomiting associated with opioids 
is affected by the specific drug and its lipid solubility profile, the dose and route of 
administration and the concomitant administration of other drugs such as  acepromazine. 
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In general, the incidence of vomiting is decreased with higher 
opioid doses, higher lipid solubility, and the prior administra-
tion of acepromazine, a dopamine antagonist.2,3,14
Multiple published studies have implicated periopera-
tive vomiting as a risk factor for postoperative aspiration 
pneumonia in canine patients. Kogan et al4 found that in 
addition to esophageal, laryngeal, and neurological disorders, 
aspiration pneumonia was associated with vomiting and 
anesthesia and had a mortality rate of 33%. Alwood et al5 
found that 22% of dogs undergoing laparotomy developed 
postoperative pulmonary complications. Of these cases, 75% 
were observed to have perioperative vomiting or regurgita-
tion (50% pre-op, 4% intra-op, 21% post-op) with a 12% 
mortality. Tart et al6 identified potential risks associated 
with aspiration pneumonia and found that ~46% had recent 
general anesthesia or sedation and 64% were observed to 
have vomited perioperatively, resulting in 20% mortality. A 
recent multicenter study examined the prevalence and risk 
factors for canine postanesthetic aspiration pneumonia. The 
anesthesia factors associated with aspiration pneumonia 
included hydromorphone, administration of intraoperative 
constant-rate infusions, use of positive inotropes, and vomit-
ing and regurgitation during or after anesthesia.7 In addition 
to decreasing the risk of postanesthetic aspiration pneumonia, 
preventing perioperative vomiting may also decrease morbid-
ity in certain specific veterinary patient populations. Patients 
such as those with penetrating eye injuries, glaucoma, head 
trauma, or intracranial disease are specific examples where 
an increase in intraocular or intracranial pressure associated 
with vomiting should be avoided.
In addition to decreasing morbidity and mortality, pre-
venting or treating perioperative vomiting and signs of nausea 
may also be considered an animal welfare issue. Human 
anesthesia patients report high levels of discomfort, distress, 
and dissatisfaction associated with perioperative nausea 
and vomiting. In fact, nausea and vomiting are the leading 
adverse events reported by human patients and are strongly 
related to patient dissatisfaction.9. Along with pain, nausea 
and vomiting are also ranked by human anesthesiologists as 
the top anesthesia outcomes that occur frequently and are 
important to avoid.8 Nausea is considered a prodromal sign 
of vomiting that may or may not result in vomiting. It is a 
highly subjective experience, and so clinical signs may be eas-
ily overlooked in veterinary patients who cannot self-report 
their discomfort. According to Brambell’s Five Freedoms of 
animal welfare, freedom from discomfort, pain, and distress 
should be worthy goals for veterinary practitioners. Interpre-
tation of animal suffering dictates that if a human is likely to 
experience discomfort or distress under particular conditions, 
then it should be assumed that an animal of another species 
may be similarly affected.10
The importance of this issue to pet owners is reflected 
in a recent survey of dog owners presenting to a US vet-
erinary teaching hospital. Of the 104 owners surveyed, an 
overwhelming number (over 90%) had at least some worry 
regarding their dog vomiting in relation to opioid analgesics 
and anesthesia and 46% indicated that they were moderately 
worried or very worried. Ninety-three percent expressed at 
least some concern about their dog experiencing nausea and 
37.5% were moderately or very worried. When asked about 
treatment, 99% would probably or definitely choose treat-
ment to prevent vomiting and close to 96% would probably 
or definitely choose treatment to decrease or prevent nausea. 
Furthermore, owners were willing to pay as much as $50–$75 
(median and mean, respectively) for treatment, especially 
if it was recommended by their veterinarian. Most owners 
(>90%) were still likely or very likely to choose treatment 
even if they were required to arrive 1 hour earlier for their 
scheduled appointment in order to receive the treatment.11
An effective, US Food and Drug Administration-approved 
drug is available to prevent perioperative nausea and vomit-
ing. Maropitant is a potent, selective neurokinin-1 (NK-1) 
antagonist which blocks the binding of the neurotransmitter 
Substance P (SP). SP is found in high concentrations in both 
the chemoreceptor trigger zone (CTZ) and the vomiting 
center (VC) and is a key neurotransmitter involved in vom-
iting. NK-1 antagonists work at both the CTZ and VC and, 
therefore, provide broad-spectrum inhibition of emesis. The 
remainder of this article will summarize published articles 
regarding the perianesthetic use of maropitant in dogs and 
cats and conclude with clinical recommendations based on 
these studies.
Background information
Tachykinins are a highly conserved group of peptides in 
mammalian species and are involved in many bodily pro-
cesses, including neurotransmission and inflammation. The 
three primary tachykinins are SP, neurokinin A, and neuroki-
nin B, and the three types of tachykinin receptors are based 
on their ligands.12 The NK-1 receptor has preferential affinity 
for SP, whereas NK-2 binds neurokinin A and NK-3 binds 
neurokinin B.12 NK-1 receptors are found in both the central 
nervous system and peripheral tissues and are involved in 
pain transmission, vasodilation, modulation of the inflamma-
tory response, as well as the sensory neuronal transmission 
involved in stress, anxiety, and emesis.12 The ubiquitous 
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Perioperative maropitant
nature of SP and NK-1 receptors in many biological functions 
including upregulation in pathological conditions makes it 
an important target for pain and vomiting and potentially 
depression, migraine, addiction, neuronal degeneration, and 
infection in human medicine.12 In human medicine, clinical 
development has focused on the drug aprepitant and its intra-
venous prodrug fosaprepitant for the treatment of anesthesia 
and chemotherapy-induced nausea and vomiting.12
Central neurologic control of vomiting involves two ana-
tomically and functionally separate units, the emetic center or 
VC and the CTZ (Figure 1). The VC consists of the nucleus 
tractus solitaries (NTS) and the dorsal motor nucleus of the 
vagus, which are both located in the medulla oblongata.13 The 
VC lies within the blood–brain barrier (BBB) and receives 
input from four areas: the CTZ, the gastrointestinal tract and 
other abdominal organs, the vestibular apparatus (vomiting 
associated with motion sickness), and the cerebral cortex 
(psychogenic vomiting).13 The CTZ is in the area postrema 
(AP) located on the dorsal surface of the medulla oblongata 
adjacent to the fourth ventricle. The CTZ lies outside the 
BBB and is responsive to circulating emetogens including 
drugs (such as opioids), but also uremic toxins; electrolyte, 
osmolar, and acid–base disorders; as well as metabolic 
derangements such as diabetic ketoacidosis.13 The CTZ 
sends signals to the VC, primarily the NTS, and the central 
pattern generator (CPG), which controls swallowing, gastric 
and lower esophageal tone and respiration and, thus, elicits 
the motor and autonomic responses associated with vomit-
ing.13 NK-1 receptors and SP are present in the NTS, dorsal 
motor nucleus of the vagus, and the AP. NK-1 antagonists act 
at these sites and the CPG or the pathway between the NTS 
and CPG to provide broad-spectrum inhibition of vomiting 
caused by both peripheral and central pathways.
Opioids can have emetic or antiemetic effects depend-
ing on the lipid solubility of the specific drug, the dose, and 
route of administration. The emetic effects are thought to 
be the result of stimulation of delta opioid receptors in the 
CTZ (outside the BBB), and the antiemetic effects are due 
to stimulation of mu receptors at the VC.14 Low doses of 
morphine (0.3 mg/kg IV) results in a 100% (6/6) incidence 
of vomiting, whereas higher doses (2.0 mg/kg) results in 
0% (0/28) incidence in vomiting and also prevents vomiting 
induced by apomorphine.14 It is postulated that the lower dose 
does not cross the BBB and stimulates the CTZ, resulting 
Figure 1 Central neurologic control of vomiting involves two anatomically and functionally separate units; the VC or emetic center and the CTZ. 
Notes: The CTZ lies outside the BBB and is responsive to circulating emetogens. These emetogenic stimuli act either peripherally by stimulating vagal or sympathetic 
afferents or centrally by stimulation of the CTZ. All stimuli are mediated through the VC, regardless of the cause. The VC integrates efferent input from a number of sources 
including the cerebral cortex (psychogenic vomiting), vestibular input arising from the semicircular canals (vomiting associated with motion sickness or vestibular disorders), 
vagal and sympathetic fibers, especially from the gastrointestinal system, and the CTZ. Key neurotransmitter receptors involved in the emetic response include: serotonin 
(5-HT), NK-1, dopamine (D2), histamine (H1), cholinergic (ACh), and mu opioid. Since stimulant pathways converge at the level of the VC, effective blocking of the vomiting 
reflex at this level is effective in preventing emesis, whether it is generated centrally or peripherally.
Abbreviations: ACh, acetylcholine; BBB, blood–brain barrier; CTZ, chemoreceptor trigger zone; GABA, gamma amino butyric acid; NK-1, neurokinin-1; VC, vomiting 
center.
Mechanoreceptors &
chemoreceptors
(stomach, intestine etc.)
(5HT, D2, ACh, H1, NK1)
CTZ
(5HT, D2, NK1)
Vestibular center
(H1, ACh)
Higher cortical centers
(Cortex, thalamus, hypothalamus)
(GABA. H1)
VC
(5HT, H1, ACh, NK1, mu)
Vagus nerve
(D2, 5HT, ACh)
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in vomiting. The higher dose crosses the BBB to reach the 
VC and prevents vomiting. The route of administration also 
affects the incidence of vomiting. The incidence of vomit-
ing for hydromorphone is highest after subcutaneous (SC) 
administration (75% for 0.1 mg/kg and 100% for 0.5 mg/
kg) compared to 44%–66% for intramuscular (IM) doses of 
0.1 mg/kg.2,20 The incidence of vomiting after IV adminis-
tration of hydromorphone is 33% (3/9) for 0.1 mg/kg and 
0% (0/7) for 0.5 mg/kg.3 Highly lipid soluble opioids such 
as fentanyl do not cause vomiting due to their effect on the 
VC. The incidence of vomiting at doses of 5.0 and 10 μg/kg 
IV was 0% (6/6 and 12/12, respectively), and the 10 μg/kg 
dose prevented vomiting caused by apomorphine.14
Maropitant is an NK-1 receptor antagonist which acts by 
inhibiting the binding of SP and blocking its pharmacologic 
action. It is the first drug in its class to be approved to treat 
and prevent vomiting specifically in dogs and cats. It been 
shown to significantly decrease vomiting from both centrally 
acting (apomorphine) and peripherally acting emetogens 
(syrup of ipecac).15 In the proprietary injectable formulation 
of maropitant (Cerenia), contains maropitant (10 mg/mL), 
sulphobuyether-β-cyclodextrin (SBECD, 63 mg/mL), and 
the preservative 3.3 mg meta-cresol (3.3 mg/mL) and water 
for injection.16 The cyclodextrin (SBECD) forms a molecular 
cavity that entraps maropitant and limits the amount of free 
drug, preventing direct contact with biological tissues. Cyclo-
dextrins are used in drug formulations to improve solubility 
and reduce injection-related irritation without loss of thera-
peutic benefits.17 It is thought that the unbound maropitant is 
responsible for the local irritation and injection pain observed 
in the postmarketing surveillance of Cerenia. Narishetty et al17 
found that the binding constant of the maropitant–SBECD 
complex exhibited an inverse relationship with temperature; 
as temperature increased, binding decreased, leading to more 
unbound maropitant and increased injection pain. There is an 
approximate four-fold decrease in complex binding at room 
temperature (22°C, 72°F) and a ten-fold decrease in binding 
of the complex at 37°C (98.6°F) compared to refrigerated 
temperatures (4°C, 39°F).16 This same study evaluated pain 
on injection at different temperatures. Injection pain was 
compared at 14°C (57°F), 22°C (72°F), and 37°C (98.6°F).17 
Only 6% of dogs exhibited pain on injection in the refrigerated 
Cerenia group vs 26% for the room temperature and warmed 
Cerenia. Visual analog scales (VAS) for pain were significantly 
higher in dogs administered room temperature (25°C, 77°F) 
vs refrigerated (4°C, 39°F) Cerenia.17 Cerenia remains stable 
and does not degrade at room temperature; however, there 
is an increased likelihood for maropitant to dissociate from 
SCECD, producing more unbound maropitant and increased 
pain on injection. It is now recommended that once the vial 
is opened, it should be stored at refrigerated temperatures 
(36°F–46°F, 2°C–5°C), where there should be minimal to no 
free maropitant. Maropitant should be administered immedi-
ately upon removal to minimize injection pain. The increased 
binding of the maropitant–SBECD complex should decrease 
the incidence and severity of injection pain.17
The injectable maropitant (Cerenia) formulation is dosed 
at 1.0 mg/kg and can be administered SC in dogs aged 2–4 
months for up to 5 days. In dogs 4 months of age and older, 
it can be also be administered slowly IV over 1–2 minutes. It 
should be administered at least 45–60 minutes prior to medi-
cations that may cause vomiting, including chemotherapeutic 
agents. In cats 4 months of age and older, 1.0 mg/kg maropitant 
can be administered either SC or IV slowly over 1–2 minutes 
once a day for up to five consecutive days. Maropitant citrate 
oral tablets are available in 16, 24, 60 and 160 mg. The tablets 
are approved for up to 5 days in dogs 2–7 months of age for 
the prevention of acute vomiting, and in dogs greater than 7 
months of age until resolution of vomiting. In dogs that are 
actively vomiting, it is recommended that an initial dose of 
injectable maropitant be administered. Thereafter, dosing may 
be accomplished with either the injectable or tablet formulation. 
Maropitant citrate tablets are also approved for prevention of 
vomiting due to motion sickness in dogs 4 months of age and 
older. Maropitant should be dosed at a minimum of 8.0 mg/
kg at least 2 hours prior to travel and for up to two consecutive 
days. A small amount of food should be given with the maropi-
tant tablets to decrease vomiting and signs of nausea from the 
medication itself.16 The label includes a warning that the use of 
the injectable or tablet formulations of maropitant has not been 
evaluated in dogs or cats used for breeding or that are pregnant 
or lactating. Puppies younger than 11 weeks had evidence of 
bone marrow hypoplasia which may be related to NK-1 recep-
tors presence in bone marrow and their role in hematopoisis.12 
Injectable maropitant is metabolized by the cytochrome P450 
enzymes CYP3A and CYPD15 in dogs and by CYP1A in cats.16 
The pharmacokinetic parameters of maropitant in dogs and cats 
are illustrated in Tables 1 and 2, respectively.
Treatment/prevention of 
perioperative vomiting and signs of 
nausea
Hydromorphone studies in dogs
The first study to examine maropitant as an agent to prevent 
perianesthetic vomiting and signs of nausea concluded that 
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when maropitant (1.0 mg/kg SC) was administered 1 hour 
prior to opioid premedication, vomiting, retching, and signs 
of nausea were prevented.20 Eighteen dogs being admitted 
for elective orthopedic procedures were dosed with either 
saline or maropitant 1 hour prior to premedication with 
hydromorphone (0.1 mg/kg IM). Dogs were observed for 
30 minutes for vomiting, retching, and/or signs of nausea. 
Vomiting was defined as expulsion of stomach contents from 
the mouth, whereas retching was forceful contraction of the 
abdominal muscles without expulsion of stomach contents. 
Signs interpreted as nausea included salivation, licking of 
lips, and increased or exaggerated swallowing motions. 
None of the dogs in the maropitant group vomited, retched, 
or exhibited signs of nausea. However, all of the dogs in the 
saline (placebo) group either vomited (6/9, 66%), retched 
(1/9, 11%), or displayed signs of nausea (2/9, 22%).20
The perceived barriers to preanesthetic treatment with 
maropitant to prevent opioid-induced vomiting are the 
waiting time for the onset of action of maropitant and also 
pain caused by injection. IV administration has recently 
been added to the Cerenia label and would speed the onset 
of action and avoid the pain associated with SC administra-
tion. However, IV administration has been associated with 
a decrease in blood pressure in healthy dogs.36 Oral admin-
istration would avoid the pain caused by SC injection and 
could be administered at home by the owner the evening 
prior to elective anesthesia. A subsequent study evaluated the 
effectiveness of the oral tablets in preventing vomiting and 
signs of nausea in dogs premedicated with hydromorphone.21 
Forty dogs were dosed with either placebo or maropitant 
citrate tablets (2.0–4.0 mg/kg) per oral (PO) 2 hours prior 
to hydromorphone (0.1 mg/kg) IM. Dogs were observed for 
vomiting and signs of nausea using the same definitions as the 
previous study. In addition, the signs of nausea were subjec-
tively graded as none, mild, moderate, or severe. Maropitant 
prevented vomiting, but there was no significant difference 
between maropitant and placebo in the incidence of signs of 
nausea (12/20, 60% vs 11/20, 55% respectively). In addi-
tion, 10/12 of the maropitant-treated dogs were subjectively 
assessed as exhibiting moderate to severe signs of nausea, 
whereas 14/16 of the placebo-treated dogs were assessed to 
have only mild clinical signs of nausea. In this study, although 
oral maropitant prevented vomiting, it did not prevent signs 
of nausea and, in fact, caused more severe signs of nausea 
associated with hydromorphone administration.21
Another study by Hay Kraus22 evaluated the effect of the 
dosing interval time on the efficacy of maropitant for preven-
tion of vomiting and signs of nausea in dogs, as defined in 
previous studies. Fifty client-owned dogs were dosed with 
maropitant (1.0 mg/kg SC) simultaneously (time 0) or 15, 
30, 45, and 60 minutes prior to administration of hydromor-
phone (0.1 mg/kg IM). Sixty percent (6/10) of dogs in the 
time 0 group vomited. Vomiting was significantly reduced 
by 15 minutes (2/10, 20%) and prevented in all dogs by 30 
minutes. Signs of nausea were significantly reduced only at 
the 60 minute time interval.22 According to Benchaoui et al,18 
maropitant (1.0 mg/kg SC) achieves a peak plasma concentra-
tion of 92 ng/mL at 0.75 hours. On the basis of this dosing 
interval study, the pharmacodynamics of the antiemetic activ-
ity of maropitant is achieved well before the time required 
for the drug to reach peak plasma concentration, especially 
when administered prior to emetic challenge. However, signs 
of nausea are significantly decreased only by waiting the full 
60 minutes between maropitant and opioid dosing.
Table 1 Pharmacokinetics in Beagle dogs (mean ± SD)
PK parameter IV (1.0 mg/kg) SC (1.0 mg/kg) PO (2.0 mg/kg) PO (8.0 mg/kg)
Cmax (ng/mL) 1920±653 92±34 81±32 776±604
Tmax (hr) 0.03 0.75 1.9 1.7
T1/2 6.25 7.75 4.0 5.5
Notes: The bioavailability is 91%, 24%, and 37% after SC injection of 1.0 mg/kg, 2.0 mg/kg PO, and 8.0 mg/kg PO, respectively. Data from Benchaoui et al.18
Abbreviations: Cmax, peak plasma concentration; IV, intravenous; PO, per oro; SC, subcutaneous; Tmax, time to Cmax.
Table 2 The pharmacokinetic data from label informationa and Hickman et alb after IV, SC, and PO dose of maropitant in cats is 
illustrated in the table below
Pharmacokinetic parameter 1.0 mg/kg IV 1.0 mg/kg SC 1.0 mg/kg PO
Cmax (ng/mL) 988
a 269b 156b
Tmax (h) NA 0.43
a, 0.5–2.0b 2–3b
T1/2 (h) 4.9
a 6.6a
Notes: The reported bioavailability is 117% after SC administration and 50% after oral administration. The time to peak plasma concentration is reported to range from 26 
minutes (label) up to 2 hours.19 Data from aCerenia (tablets and injectable marketing package insert), Zoetis Inc.16 and bHickman et al.19
Abbreviations: Cmax, peak plasma concentration; IV, intravenous; PO, per oro; SC, subcutaneous; Tmax, time to Cmax.
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Claude et al23 evaluated the effects of maropitant or 
acepromazine on the adverse effects, including vomiting, 
signs of nausea, pytalism, and panting associated with 
hydromorphone administration in dogs. Sixty healthy female 
dogs scheduled for ovariohysterectomy (OHE) were dosed 
with saline (placebo control), maropitant (1.0 mg/kg SC), 
or acepromazine (0.02 mg/kg IM) 30–45 minutes prior to 
hydromorphone (0.2 mg/kg IM). The incidence of vomiting 
was none (0%), 53%, and 87% for the maropitant, aceproma-
zine, and saline groups, respectively.23 In this study, signs 
of nausea were defined as excessive licking of the lips and 
swallowing and a hunched posture. The incidence of nausea 
was not significantly different between groups; (3/15 (20%), 
7/15 (47%), and 9/15 (60%) for the maropitant, aceproma-
zine, and control group, respectively). Pytalism (increased 
salivation) was evaluated as a separate adverse effect and was 
significantly increased in the maropitant group (11/15, 73%) 
compared to control (7/15, 47%) and acepromazine (3/15, 
20%).23 The authors did not speculate on a reason for the 
association of increased salivation compared to other stud-
ies; however, from the dosing interval study by Hay Kraus,22 
it can be noted that at least 60 minutes is required between 
dosing of maropitant and hydromorphone to significantly 
decrease signs of nausea.22 Another factor may be related to 
the hydromorphone dose of 0.2 mg/kg, which was twice that 
of the other studies. Although it is well documented that the 
incidence of vomiting with opioids decreases with increasing 
opioid dose, there is no documentation regarding the effect 
of dose on the incidence or severity of salivation or signs of 
nausea in dogs or other veterinary species.
Morphine studies in dogs
Koh et al,24 evaluated the effects of maropitant, acepromazine, 
and electroacupunture on the incidence of vomiting and signs 
of nausea associated with morphine administration in dogs. 
Two-hundred twenty two dogs received 1 of 6 treatments: 
saline, maropitant (1.0 mg/kg SC), acepromazine (0.05 mg/
kg IM), or electroacupunture at either 1 acupoint (pericar-
dium-6) or 5 acupoints (pericardium-6, stomach-36, gallblad-
der-34, bladder-20 and bladder 21) or a sham (non-acupoint) 
20 minutes prior to morphine (0.5 mg/kg IM). In this study, 
the signs of nausea included ptylaism, lip-licking, swallow-
ing, nervousness, restlessness, and signs of depression. Each 
of three categories of signs of nausea (lip-licking/swallowing, 
salivation, and attitude/mentation/posture) were scored 1 to 4 
(1 = none, 4 = worst possible signs) and the mean nausea score 
at each time point was determined. Maropitant significantly 
decreased, but did not prevent vomiting and retching (14/37, 
37.8% vs 28/37, 75.7% for saline group) when administered 
20 minutes prior to morphine. Acepromazine significantly 
decreased the incidence of signs of nausea (3/37, 8.1%).24 
Both acepromazine and electroacupunture appeared to help 
decrease the severity of signs of nausea after morphine 
administration.
The efficacy of maropitant in preventing vomiting and 
salivation caused by morphine and acepromazine premedi-
cation was investigated by Lorenzutti et al.25 Sixty female 
dogs admitted for elective OHE were administered either 
saline control or maropitant (1.0 mg/kg SC) dosed either 
simultaneously or 30 minutes prior to morphine (0.5 mg/
kg) and acepromazine (0.05 mg/kg) IM. Maropitant had 
no significant effect on the incidence of vomiting or saliva-
tion when administered at the same time as morphine and 
acepromazine. However, when maropitant was dosed 30 
minutes prior to morphine and acepromazine, the incidence 
of vomiting was significantly decreased but not completely 
prevented; 3/20 (15%) for maropitant and 10/20 (50%) for 
saline control. There was no significant decrease in salivation 
when maropitant was dosed 30 minutes prior to morphine 
and acepromazine.25
Lorenzutti et al26 compared the incidence of vomiting and 
signs of nausea in dogs administered maropitant (1.0 mg/kg) 
or metoclopramide (0.5 mg/kg) or saline 45 minutes prior to 
premedication with morphine (0.5 mg/kg) and acepromazine 
(0.05 mg/kg). Maropitant successfully prevented vomiting 
in all dogs compared to an incidence of 38% in the meto-
clopramide group and 71% in the saline group. However, 
there was no significant difference in the incidence of signs 
of nausea (definded as ptyalism, lip-licking, increased fre-
quency of swallowing) between the groups. This study also 
documented a higher incidence of injection discomfort with 
maropitant (48%) compared to 9.8% for metoclopramide and 
4.8% for saline.26 Ramsey et al27 also assessed the efficacy of 
maropitant SC to prevent vomiting and signs of nausea after 
morphine premedication. In addition, this study assessed the 
quality of recovery from anesthesia and the return to normal 
feeding postoperatively. Sixteen male and 16 female Beagle 
dogs were dosed with either maropitant or saline 45 minutes 
prior to premedication with morphine (0.5 mg/kg IM) fol-
lowed by propofol induction and isoflurane anesthesia for 
routine castration or OHE. Signs of nausea included excessive 
salivation, increased/exaggerated swallowing, licking of lips, 
hunched posture, piloerection, restlessness, and vocalization. 
The severity of nausea signs was evaluated using a VAS 
where the observer placed a mark along a 100 mm line where 
the far left indicated no nausea and the far right indicated 
 
Ve
te
rin
ar
y 
M
ed
ici
ne
: R
es
ea
rc
h 
an
d 
Re
po
rts
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
9.
18
6.
17
6.
21
7 
on
 0
6-
De
c-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Veterinary Medicine: Research and Reports 2017:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
47
Perioperative maropitant
the worst possible nausea. None of the maropitant-treated 
dogs vomited compared to 15/16 of the saline-treated dogs. 
Maropitant significantly decreased but did not prevent signs 
of nausea (increased salivation, licking of the lips, restless-
ness, hunched posture, and vocalization) preoperatively. 
Maropitant-treated dogs had significantly better anesthesia 
recovery scores compared to saline dogs, where 25% were 
documented to experience a difficult or rough recovery based 
on behavioral observations. Postoperatively, the female dogs 
exhibited a significantly higher incidence of signs of nausea 
compared to males, which the authors attributed to the effects 
of intra-abdominal surgery. Females in the maropitant group 
exhibited less signs of nausea postoperatively compared to 
saline-treated females. The maropitant-treated dogs also had 
a faster return to feeding, with ~67% returning to feeding 
(consuming at least 100 gms of food) 6 hours PO compared 
to only 33.3% of saline-treated dogs. By 20 hours PO, 93% 
(all but one) of maropitant-treated dogs had returned to feed-
ing compared to only 46% of placebo dogs. Dogs treated 
with maropitant also ate significantly more food, with a 
mean food consumption of 190 gms vs only 39 grams for 
saline dogs.27 This study demonstrated the many advantages 
of using maropitant as a preanesthetic agent, especially 
when used in conjunction with mu-agonist opioids, and 
in females undergoing OHE surgery. Maropitant prevents 
opioid-induced vomiting and decreases signs of nausea both 
preoperatively and postoperatively in females undergoing 
OHE surgery. Additionally, maropitant may smooth recovery 
from anesthesia and improve postoperative time to return to 
feeding and food intake, thus reversing the negative caloric 
energy balance associated with anesthesia and surgery and 
improving overall patient recovery.
Effects of maropitant on 
gastroesophageal reflux
Perianesthetic aspiration pneumonia has been associated with 
both perianesthetic vomiting and gastroesophageal reflux 
(GER). Anesthesia-associated GER may also lead to esopha-
gitis and esophageal stricture. However, the mechanisms of 
these physiologic processes are completely different. Vomit-
ing is defined as the forceful expulsion of gastric contents 
from the oral cavity and is triggered by the VC which receives 
input from the CTZ, as well as the gastrointestinal tract, 
cerebral cortex, and vestibular apparatus. GER is defined as 
the passive reflux of gastric fluid contents into the esophagus 
and a measured pH <4.0. The primary barrier to GER is the 
tone of the lower esophageal sphincter, which is made up of 
muscle layers at the gastroesophageal junction. Injectable 
and inhalant anesthetic drugs contribute to GER by causing 
relaxation of the lower esophageal sphincter. The incidence 
of GER has been reported as 10%–55% in dogs and as high 
as 50% in cats under anesthesia for dentistry procedures.28–30 
Therefore, prevention of anesthesia-associated GER, in addi-
tion to vomiting, would also improve patient morbidity and 
mortality. Johnson evaluated the effect of IV maropitant on 
the incidence of vomiting and GER in dogs premedicated 
with hydromorphone and acepromazine.31 Twenty-six dogs 
admitted for elective surgical procedures were administered 
either saline or maropitant (1.0 mg/kg IV) 45–60 minutes 
prior to premedication with hydromorphone (0.1 mg/kg) and 
acepromazine (0.03 mg/kg) IM. The dogs were observed for 
vomiting/retching, and esophageal pH was monitored during 
inhalant anesthesia and surgery. Maropitant prevented vomit-
ing/retching compared to saline control (0/13 vs 6/13, 46%). 
However, there were no significant differences between the 
groups for the incidence of GER (4/13 for maropitant, 6/13 
for saline) or the number of reflux events.31 This is likely due 
to differences in the physiologic mechanisms of vomiting ver-
sus GER, but may also be due to the small study sample size.
Treatment of perioperative 
vomiting and signs of nausea in 
feline patients 
Hickman et al19 performed the original safety and efficacy 
studies for the use of maropitant for the prevention of vomit-
ing and motion sickness in cats. In the tolerability study, six 
cats were observed for their reaction to the SC injection of 
maropitant. Interestingly, no abnormal behavior was observed 
at the clinical dose of 1.0 mg/kg SC; however, the commercial 
formulation was not used in that study and it was not noted 
if the formulation was refrigerated. Maropitant administered 
as a single dose and for 4 days was found to be well toler-
ated by cats. There were no changes in behavior, appetite, or 
level of consciousness. Likewise, at doses up to 5.0 mg/kg 
administered for 15 days, no adverse effects were noted on 
physical exam, hematology, serum chemistry, urinalysis, or 
coagulation parameters. The only drug-related histopatho-
logic findings were related to inflammation and fibrosis at the 
injection site. The antiemetic efficacy was confirmed using a 
xylazine challenge (0.44 mg/kg IM) at 2 and 24 hours post 
maropitant administration. Maropitant, administered at 1.0 
mg/kg SC, PO, or IV decreased the mean number of vomit-
ing events by 76%, 90%, and 100%, respectively, compared 
to control. At 24 hours, maropitant was effective in reducing 
the incidence of vomiting associated with xylazine by 66% 
and significantly decreased VAS nausea scores.19
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As noted above, Hickman et al19 noted no abnormal 
behavior in cats receiving 1.0 or 2.5 mg/kg SC. However, the 
commercial formulation was not used in that study. Studies 
by the manufacturer using the commercial formulation for 
a supplemental drug application to add an indication for 
the treatment of vomiting in cats all documented moderate 
to marked response to SC injection characterized by vocal-
ization, retreating, and hissing.32 In the US clinical field 
effectiveness study in cats, 88/133 (66%) displayed either no 
response or a mild response where the cat seemed aware of 
the injection but did not protest compared to saline control 
(60/62, 96.8%).32 However, a moderate response consisting 
of the cat objecting to the injection by retreating or vocalizing 
occurred in 30/133 (22.6%) of cats.32 Fifteen of 133 (11.3%) 
were documented to have a significant response to injection 
by retreating, hissing, scratching, and vocalizing.32 In the 
subsequent margin of safety study, assessment of behavioral 
responses and assessment of the severity of restraint required 
for the SC injection were performed.32 At the recommended 
dose of 1.0 mg/kg, 63% of cats had a normal behavioral 
response in that they seemed aware of the injection but did 
not protest.32 However, approximately 37% of cats were 
assessed to have a moderate or marked reaction to the injec-
tion, which included vocalization, scratching, or biting, and 
a persistent response to the injection site.32 Other behaviors 
associated with injection included licking, scratching, or bit-
ing at the injection site, growling, urination, salivation, and 
vomiting.32 Approximately half of the cats required moderate 
to substantial increase in manual restraint of the cat and/or 
use of a cat bag or other safety equipment.32
Martin-Flores et al33 were the first to evaluate the use of 
maropitant for prevention and treatment of perianesthetic 
vomiting and signs of nausea in cats. In that study, 66 cats 
were treated with either maropitant (1.0 mg/kg SC) or 
saline 20 hours prior to premedication with dexmedeto-
midine (20 μg/kg) and morphine (0.1 mg/kg) IM. Blinded 
observers evaluated the cats for vomiting/retching, signs of 
nausea (defined as sialorrhea, excessive lip-licking), and the 
response to injection. Aversive behavior in response to injec-
tion was evaluated using a VAS where the observer placed 
a mark over a 10 cm straight line on which the left aspect 
of the line indicated no response and the right represented 
the most adverse reaction possible. Maropitant significantly 
decreased vomiting (1/32, 3.0%) compared to saline (20/34, 
59%). Maropitant also significantly decreased, but did not 
prevent, retching (6/32, 19%) compared to saline (19/34, 
56%). Signs of nausea were decreased (11/32, 34% vs 19/34, 
56%) but did not reach statistical significance. The VAS 
scores for cats receiving maropitant SC were significantly 
higher than the cats receiving saline. In fact, over 27% of 
cats in the maropitant group were assigned a VAS score of 
7 or greater, compared to only 4% of the saline cats. The 
aversive behaviors consisted primarily of vocalization and 
attempts to escape restraint. One cat in the maropitant group 
received a VAS score of ten, indicating the worst reaction 
imaginable to an SC injection.33 To the author’s knowledge, 
there are no studies on the incidence of perioperative aspira-
tion pneumonia in cats. However, one may assume that, like 
canine patients, the incidence may be low but mortality high 
and may be associated with many of the same risk factors, 
including perianesthetic vomiting. However, the dilemma 
does become one of whether pretreating all cats with SC 
maropitant and causing significant discomfort is justified for 
decreasing perianesthetic vomiting and possible aspiration.
Due to concern over patient discomfort with SC maropi-
tant injection, the same investigators evaluated the efficacy of 
the oral maropitant formulation in preventing perianesthetic 
vomiting and signs of nausea.34 Signs of nausea included 
licking of the lips or sialorrhea, which was identified as 
clear or frothy fluid around the lips with or without drip-
ping. Ninety-eight cats were administered 8.0 mg (mean 
dose 2.5 mg/kg) PO 18 hours prior to premedication with 
dexmedetomidine (20 μg/kg) and morphine (0.1 mg/kg) 
IM. This was meant to simulate dosing the night before 
a planned anesthetic procedure. Maropitant significantly 
decreased, but did not completely prevent, vomiting (2/46, 
4%) compared to the control group (20/50, 40%). Maropitant 
also significantly decreased the incidence of retching in cats 
(4/46, 8% vs 20/50, 40%). As in dogs, oral maropitant did 
not significantly decrease the incidence of sialorrhea (10/46, 
21% for maropitant compared to 11/50, 22% for control). 
However, the maropitant group did have a significant decrease 
in the incidence of lip-licking (14/46, 30% vs 26/50, 52% 
for control), which may be interpreted as one of the signs of 
nausea in dogs and cats.34
Martin-Flores et al35 also evaluated the efficacy of oral 
maropitant dosed 2.0–2.5 hours prior to the same premedica-
tion protocol to simulate administration the morning of the 
anesthetic procedure. Eighty-three cats were administered 
8.0 mg (mean dose 2.9 mg/kg) PO prior to dexmedetomidine 
(20 μg/kg) and morphine (0.1 mg/kg) IM. As in the previous 
study, maropitant significantly decreased but did not prevent 
the incidence of vomiting and retching. Vomiting occurred 
in 5/39 (13%) of maropitant-treated cats compared to 14/44 
(32%) of control cats. Likewise, retching occurred in 5/39 
(13%) of maropitant cats and 16/44 (36%) of control cats. 
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In this study, maropitant did not decrease sialorrhea or lip-
licking. In fact, maropitant-treated cats experienced a higher 
incidence of sialorrhea (8/38, 21%) compared to control cats 
(4/43, 9%).35 Similar to dogs, oral maropitant is more effec-
tive as an antiemetic agent than antinausea agent.
It is clear from both the initial safety/tolerability studies 
and subsequent clinical studies that maropitant dosed SC or 
PO is effective in decreasing but not completely preventing 
vomiting/retching in cats and provides minimal protection 
against signs of nausea defined as increased salivation and/
or lip-licking. It may be more efficacious if dosed IV prior 
to an emetic challenge. Cats may be more similar to human 
patients in that monotherapy is less successful in the pre-
vention of perianesthetic nausea and vomiting, and efforts 
should include choice of drug protocols associated with lower 
incidence of nausea and vomiting.
Adjunct analgesia
NK-1 receptors and SP are found in multiple areas of the pain 
pathways, including sensory afferents, dorsal root ganglia, 
dorsal horn, and ascending projections of the spinal cord 
and higher brain centers involved in pain perception. NK-1 
receptors have been identified in the dorsal horn of the spi-
nal cord in cats and in viscera such as the esophagus, colon, 
and urinary bladder in rats.36 Greater than 80% of visceral 
afferents contain the SP neuropeptide versus only 21% of 
somatic afferents, suggesting a greater role for NK1 receptor 
antagonists in visceral antinociception than for somatic.37
Although clinical trials in humans, especially for treat-
ment of somatic type pain, have not consistently shown 
efficacy, numerous animal models have demonstrated effi-
cacy for visceral analgesia. NK-1 receptor antagonists have 
been shown to be effective for visceral pain in a number 
of laboratory animal models such as noxious bladder and 
colonic stimulation in mice and guinea pigs and colorectal 
stimulation in rabbits.36 Boscan et al36 used a validated canine 
laparoscopic ovarian pedicle stimulation model to evaluate 
the effect of maropitant on anesthetic requirements. Dogs 
were anesthetized with sevoflurane and administered maropi-
tant (1.0 mg/kg IV followed by 30 μg/kg/hr IV). Maropitant 
decreased the minimal alveolar inhalant anesthetic require-
ments (MAC) by 24% during visceral stimulation of the 
ovary and ovarian ligament. Similar results were found in 
cats, with maropitant (1.0 mg/kg IV) decreasing the MAC 
of sevoflurane by 15% using a similar ovarian stimulation 
model.37 However, in both studies and species, a higher dose 
of 5.0 mg/kg did not lead to a significant further decrease 
in the MAC of sevoflurane. A subsequent study used a tail 
clamp stimulation model in dogs to simulate stimulation of 
the somatic tissues of bone, skin, and soft tissues. Maropitant 
(5.0 mg/kg IV) decreased the MAC of sevoflurane by 16%.38 
However, the MAC did not significantly change significantly 
when the maropitant (1.0 mg/kg) was administered via an 
epidural catheter.38
Marquez et al39 performed a blinded clinical trial com-
paring maropitant (1.0 mg/kg) and morphine (0.5 mg/kg) 
SC in healthy female dogs admitted for elective OHE. Dogs 
were administered morphine or maropitant 30 minutes prior 
to induction with propofol followed by inhalant anesthesia. 
Dogs were monitored for heart rate, systolic blood pressure, 
end-tidal isoflurane concentration, pain assessment via VAS 
and Colorado Acute Pain Scale (CSU), recovery quality, and 
return to feeding. Dogs in the maropitant group had lower 
heart rates, systolic blood pressure, and inhalant anesthetic 
requirement compared to dogs receiving morphine. At 
extubation, maropitant-treated dogs had significantly lower 
VAS and CSU pain scores. However, there was no significant 
difference in pain scores at any subsequent time point and no 
significant difference in the requirement for rescue analgesia 
between groups. Maropitant-treated dogs were significantly 
more likely to eat within 3 hours of extubation (65%) com-
pared to only 15% in the morphine group.39
Fukui et al40 evaluated the effect of maropitant, carprofen, 
or the combination of the two on the minimum alveolar con-
centration for blunting the adrenergic response (MAC-BAR) 
of sevoflurane in dogs. The MAC-BAR is the minimum anes-
thetic concentration which prevents an autonomic response 
to noxious stimulus and provides information related to 
intraoperative neuroendocrine stress, whereas traditional 
MAC reflects suppression of motor neurons in the ventral 
horn of the spinal cord. Six Beagle dogs were dosed with 
either maropitant (1.0 mg/kg) or carprofen (4.0 mg/kg) alone, 
or both maropitant and carprofen or saline 1 hour prior to 
MAC-BAR determination. MAC-BAR was measured during 
anesthesia with sevoflurane by determining the response to a 
noxious electrical stimulus (50 Hz, 10 msec) applied to the 
gingiva using an electrical stimulator. In this study, MAC-
BAR was significantly reduced with maropitant and carprofen 
alone and the combination compared with saline. There was 
no significant difference in the mean percentage of MAC-
BAR of sevoflurane reduction between maropitant (15%), 
carprofen (10.2%), or the combination (16.2%), indicating 
a lack of additive effect of the two drugs.40 This study helps 
to further elucidate the roles of these two agents in provid-
ing analgesia. Maropitant provides analgesia by blocking 
the pharmacologic effect of SP at the spinal cord and brain 
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through its antagonism at the NK-1 receptors. Nonsteroi-
dal anti-inflammatory drugs (NSAIDs), such as carprofen 
produce peripheral analgesia and anti-inflammatory effects 
by inhibiting prostaglandin production via inhibition of 
cyclooxygenase. However, there is increasing evidence that 
NSAIDs also have antinociceptive effects in the central 
nervous system by decreasing prostaglandin facilitated 
release of SP from central C-fiber nerve terminals. It was 
postulated that, in this study, inhibition of SP release from 
the C-fibers by carprofen did not further reduce MAC-BAR 
since maropitant had already blocked binding of Substance P 
to NK-1 receptors in the spinal cord. Maropitant may provide 
similar central analgesia to NSAIDs both in MAC-sparing 
capability and central nociceptive pathways but provide a 
more favorable side effect profile than NSAIDs.
Clinical recommendations
From the body of research and clinical studies above, there 
is a preponderance of evidence of the advantages of using 
maropitant as a preanesthetic agent in both dogs and cats, 
especially when used in conjunction with mu-agonists and 
in females undergoing OHE surgery. Maropitant prevents 
opioid-induced vomiting and decreases signs of nausea pre-
op and post-op in females undergoing OHE surgery. For 
canine patients, 1.0 mg/kg SC administered 1 hour prior to 
hydromorphone has been shown to prevent vomiting and 
signs of nausea. To date, the studies evaluating the effective-
ness of maropitant prior to morphine premedication have 
only allowed 20–45 minutes after maropitant administration, 
resulting in a significant decrease, but not complete elimi-
nation of, vomiting and signs of nausea. Since morphine is 
less lipid soluble than hydromorphone and may be a stronger 
emetogen than hydromorphone, the recommendation would 
be to allow the full 1 hour prior to morphine administration 
to allow full onset of action of maropitant SC. To minimize 
injection pain, opened vials of maropitant should be stored 
at refrigerated temperatures (36°F–46°F, 2°C–5°C) and 
administered immediately. Oral dosing (2.0–2.5 mg/kg) of 
maropitant in dogs 2 hours prior to hydromorphone admin-
istration is effective in preventing vomiting; however, it does 
not prevent signs of nausea and appears to actually increase 
the severity of visible signs of nausea, including salivation, 
licking of lips, and increased swallowing.
Subcutaneous administration of maropitant in cats is effec-
tive in decreasing, but not eliminating, vomiting and signs of 
nausea prior to morphine/dexmedetomidine premedication. 
However, feline patients exhibit significant aversive behaviors 
and pain upon SC injection, and therefore oral administration 
at least 2–3 hours prior to opioid premedication may be a more 
humane option. Oral maropitant significantly decreases but 
does not eliminate vomiting and signs of nausea associated 
with morphine/dexmedetomidine premedication in cats. Cur-
rently, there are no studies evaluating the effect of refrigeration 
of maropitant on injection pain in cats.
IV administration has recently been added to the label 
specifictions. Peak plasma concentrations occur within min-
utes of IV injection, and therefore should effectively prevent 
vomiting and signs of nausea related to opioid administra-
tion. However, to date, no dosing interval studies have been 
completed assessing effectiveness prior to emetogen/opioid 
challenge. The label recommends IV administration slowly 
over 1–2 minutes. This will help to avoid or ameliorate 
hypotension associated with IV administration. However, the 
author would also recommend monitoring of blood pressure 
during and after IV administration, especially in nonhealthy 
or critically ill patients.
Additional documented advantages to adding maropitant 
to perianesthetic regimes are smoother recovery from anesthe-
sia, adjunct analgesia, especially in female patients for OHE, 
and inhalant MAC sparing. Dogs treated with maropitant also 
return to feeding earlier and eat more food postoperatively, 
helping to speed recovery and healing and reversing the 
negative energy balance often associated with surgery and 
anesthesia. Smooth recovery and faster return to eating may 
allow improved overall patient recovery, earlier discharge, 
decreased expense, and increased owner satisfaction. Lastly, 
canine owners are concerned about their pets experiencing 
nausea and vomiting associated with anesthesia and pain 
medications and are willing to pay for effective prevention.
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